NervGen Pharma Corp Reports Q1 2025 Financial Results and Provides Operational Updates

Vancouver, British Columbia — NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company focused on developing neuro-reparative therapeutics, has released its financial and operational results for the first quarter ended March 31, 2025. The company, which specializes in creating treatments for spinal cord injury, multiple sclerosis, Alzheimer’s disease, nerve damage, and neurodegenerative diseases, continues to make significant strides in its clinical development efforts.

In the first quarter of 2025, NervGen Pharma reported a GAAP earnings per share (EPS) of -$0.06. Despite the negative EPS, the company remains focused on advancing its lead candidate, NVG-291, particularly in the treatment of spinal cord injury (SCI). Mike Kelly, NervGen’s President and Chief Executive Officer, highlighted the progress made in the clinical development of NVG-291. The last subject in the chronic cohort of the Phase 1b/2a clinical study for SCI completed their final visit, with a topline data readout expected in early June 2025. Meanwhile, the subacute cohort continues to enroll participants actively.

NervGen Pharma, listed on the TSX Venture Exchange, has a market capitalization of 221,710,000 CAD. The company’s stock closed at 3.6 CAD on May 13, 2025, with a 52-week high of 3.75 CAD on May 5, 2025, and a 52-week low of 1.65 CAD on June 4, 2024. The price-to-earnings ratio stands at -10.05, reflecting the company’s current financial performance and market expectations.

As NervGen Pharma continues its clinical trials, the company remains committed to its mission of developing innovative therapies for neurodegenerative conditions, serving clients exclusively in Canada. For more information, stakeholders can visit the company’s website at www.nervgen.com .